Effectiveness of Drug Eluting TACE in Primary HCC
NCT04048317
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
UNKNOWN
Status
75
Enrollment
OTHER
Sponsor class
Conditions
Hepatic Cell Carcinoma
Interventions
DRUG:
HepaSphere Microspheres/Doxorubicin Hydrochloride
DRUG:
Lipiodol
Sponsor
Assiut University